We conducted a systematic literature search that identified 7 studies and six outcome prediction models for cardiotoxicity in different breast cancer populations, including patients with breast cancer at any stage, ERBB2 (formerly HER2)-negative patients, ERBB2-positive patients and patients eligible for trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.